Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab in Reduced Intensity Conditioning Allo-HCT for High Risk CLL
NCT01455051Phase 2Completed
- Sponsor
- GETH-TC
- Start
- Oct 2011
- Primary completion
- Oct 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ofatumumab in chronic lymphocytic leukemia (CLL), sponsored by GETH-TC. Started Oct 2011; status: completed.
02
Drugs
ofatumumab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT01455051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01455051.